Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ayse Altintas

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
Neurology|November 19, 2024
Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSDPakeeran Siriratnam, Saif Huda, Anneke Van Der Walt, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 4, 2024
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre studyPakeeran Siriratnam, Paul Sanfilippo, Anneke van der Walt, et al.
Multiple Sclerosis and Related Disorders|February 26, 2022
The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?Sedat Sen, Asli Tuncer, Serkan Ozakbas, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 28, 2025
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 yearsJodie I Roberts, Sifat Sharmin, Dana Horakova, et al.
Multiple Sclerosis and Related Disorders|December 27, 2019
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorderAmy Kunchok, Charles Malpas, Petra Nytrova, et al.
Neurology|March 5, 2026
Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum DisorderPakeeran Siriratnam, Vilija G Jokubaitis, Anneke Van Der Walt, et al.
Neurology|October 7, 2020
Treatment Response Score to Glatiramer Acetate or Interferon Beta-1aFrancesca Bovis, Tomas Kalincik, Fred Lublin, et al.
Brain : a Journal of Neurology|May 10, 2020
Early clinical markers of aggressive multiple sclerosisCharles B Malpas, Ali Manouchehrinia, Sifat Sharmin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 1, 2019
Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotypeYuan Zhou, Suzi B Claflin, Jim Stankovich, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 16, 2026
Comparative Effectiveness of Disease-Modifying Treatments in Double Seronegative Neuromyelitis Optica Spectrum DisorderJoao Vitor Mahler, Gerome B Vallejos, Takahisa Mikami, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
Neurology|November 19, 2024
Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSDPakeeran Siriratnam, Saif Huda, Anneke Van Der Walt, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 4, 2024
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre studyPakeeran Siriratnam, Paul Sanfilippo, Anneke van der Walt, et al.
Multiple Sclerosis and Related Disorders|February 26, 2022
The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?Sedat Sen, Asli Tuncer, Serkan Ozakbas, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 28, 2025
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 yearsJodie I Roberts, Sifat Sharmin, Dana Horakova, et al.
Multiple Sclerosis and Related Disorders|December 27, 2019
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorderAmy Kunchok, Charles Malpas, Petra Nytrova, et al.
Neurology|March 5, 2026
Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum DisorderPakeeran Siriratnam, Vilija G Jokubaitis, Anneke Van Der Walt, et al.
Neurology|October 7, 2020
Treatment Response Score to Glatiramer Acetate or Interferon Beta-1aFrancesca Bovis, Tomas Kalincik, Fred Lublin, et al.
Brain : a Journal of Neurology|May 10, 2020
Early clinical markers of aggressive multiple sclerosisCharles B Malpas, Ali Manouchehrinia, Sifat Sharmin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 1, 2019
Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotypeYuan Zhou, Suzi B Claflin, Jim Stankovich, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 16, 2026
Comparative Effectiveness of Disease-Modifying Treatments in Double Seronegative Neuromyelitis Optica Spectrum DisorderJoao Vitor Mahler, Gerome B Vallejos, Takahisa Mikami, et al.
Pageof 9